View Older Stories

Jan 28, 2026 06:41AM Viridian Therapeutic (VRDN) PT Raised to $45 at Evercore ISI

Jan 7, 2026 01:03AM UBS Starts Viridian Therapeutic (VRDN) at Buy

Jan 6, 2026 03:14PM TD Cowen on Viridian Therapeutic (VRDN): 'VRDN is a Top Pick'

Jan 6, 2026 03:13PM Jefferies on Viridian Therapeutic (VRDN): 'Attractive 2026 Setup With Pot'l Launch and Pivotal Data', 'one of our Top Picks in 2026'

Jan 6, 2026 07:02AM Viridian gets FDA priority review for thyroid eye disease drug

Dec 23, 2025 09:29AM Truist Sees 'Catalyst-Rich 2026 Set-Up' for Viridian Therapeutic (VRDN)

Dec 22, 2025 07:01AM FDA accepts Viridian Therapeutics' drug application with priority review

Dec 19, 2025 09:06AM TD Cowen on Biotechnology: '10+ Potential "Thome Run" Catalysts To Watch In 2026'

Dec 18, 2025 03:57AM Goldman on Viridian (VRDN): 'believes the market can potentially grow ~2-3x at peak due to veli's and '003's potential to expand use in chronic TED'

Dec 10, 2025 06:53AM Viridian Therapeutic (VRDN) PT Raised to $47 at Wedbush, Adds to BIL

Dec 3, 2025 06:06AM William Blair Starts Viridian Therapeutic (VRDN) at Outperform

Nov 24, 2025 07:33AM Truist Securities Starts Viridian Therapeutic (VRDN) at Buy

Nov 6, 2025 04:26AM Viridian Therapeutic (VRDN) PT Raised to $45 at RBC Capital

Nov 5, 2025 12:06PM Viridian Therapeutic (VRDN) PT Raised to $48 at Stifel

Nov 3, 2025 08:34AM Viridian submits drug application to FDA for thyroid eye disease treatment

Oct 21, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Viridian Therapeutic (VRDN)

Sep 16, 2025 05:23AM BTIG Reiterates Buy Rating on Viridian Therapeutic (VRDN)

Sep 15, 2025 07:02AM Viridian completes enrollment in phase 3 thyroid eye disease trials

Sep 5, 2025 07:33AM Viridian Therapeutics (VRDN) files mixed shelf

Aug 25, 2025 07:47AM Jefferies Assumes Viridian Therapeutic (VRDN) at Buy

Aug 6, 2025 06:52AM Viridian Therapeutics, Inc. (VRDN) Reports In-Line Q2 EPS

May 21, 2025 11:36AM B.Riley Reiterates Neutral Rating on Viridian Therapeutic (VRDN)

May 20, 2025 07:01AM Viridian Therapeutics (VRDN) Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

May 7, 2025 04:31PM Viridian Therapeutics (VRDN) Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease

May 6, 2025 09:35AM Stifel on Viridian Therapeutic (VRDN): 'Rapidly Transitioning to Commercial Stage Company'

May 6, 2025 07:33AM Viridian Therapeutics, Inc. (VRDN) Tops Q1 EPS by 11c

Apr 7, 2025 07:00AM Viridian Therapeutics (VRDN) Appoints Jeff Ajer to its Board

Apr 4, 2025 07:58AM Stifel Reiterates Buy Rating on Viridian Therapeutic (VRDN)

Feb 27, 2025 07:13AM Viridian Therapeutics, Inc. (VRDN) Tops Q4 EPS by 22c

Jan 7, 2025 08:29AM Stifel Reiterates Buy Rating on Viridian Therapeutic (VRDN)

Dec 17, 2024 09:16AM RBC on Viridian (VRDN): 'Compelling THRIVE-2 Data Could Change the Game for Chronic TED & VRDN'; PT Raised

Dec 17, 2024 06:52AM H.C. Wainwright Reiterates Buy Rating on Viridian Therapeutic (VRDN)

Dec 17, 2024 06:34AM Oppenheimer Reiterates Outperform Rating on Viridian Therapeutic (VRDN)

Dec 16, 2024 07:05AM Viridian Therapeutics (VRDN) Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Nov 25, 2024 05:32AM TD Cowen Starts Viridian Therapeutic (VRDN) at Buy

Nov 14, 2024 06:57AM Viridian Therapeutic (VRDN) PT Raised to $34 at H.C. Wainwright

Nov 12, 2024 10:51AM Viridian Therapeutic (VRDN) PT Raised to $41 at Stifel

Nov 12, 2024 07:24AM Viridian Therapeutics, Inc. (VRDN) Misses Q3 EPS by 9c

Oct 28, 2024 07:19AM Needham Reiterates Buy Rating on Viridian Therapeutic (VRDN)

Oct 28, 2024 06:04AM Goldman Sachs Reiterates Buy Rating on Viridian Therapeutic (VRDN)

Sep 13, 2024 06:33AM Viridian Therapeutic (VRDN) PT Raised to $44 at RBC Capital

Sep 12, 2024 06:12AM Viridian Therapeutics (VRDN) Prices Upsized 10.67M Share Offering at $18.75/sh

Sep 12, 2024 05:07AM Viridian Therapeutic (VRDN) PT Raised to $31 at Goldman Sachs

Sep 11, 2024 07:12AM Viridian Therapeutic (VRDN) PT Raised to $38 at Needham

Sep 11, 2024 06:37AM H.C. Wainwright Reiterates Buy Rating on Viridian Therapeutic (VRDN)

Sep 11, 2024 06:25AM Viridian Therapeutic (VRDN) PT Raised to $22 at B.Riley

Sep 10, 2024 04:33PM After-hours movers: GameStop, Dave & Buster's, Viridian Therapeutics

Sep 10, 2024 04:01PM Viridian Therapeutics (VRDN) Announces Proposed $150M Share and Warrant Offering

Sep 10, 2024 01:08PM Viridian Therapeutic (VRDN) PT Raised to $40 at Stifel

Sep 10, 2024 11:41AM Viridian Therapeutic (VRDN) PT Raised to $56 at BTIG

View Older Stories